The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
PURPOSE: Circular RNAs (circRNA) represent a novel class of widespread and diverse endogenous RNAs that regulate gene expression in mammals. microRNA-7 (miR-7) is a well-demonstrated suppressor of hepatocellular carcinoma (HCC). Recent studies have showed that one such circRNA, ciRS-7 (also termed as Cdr1as) was the inhibitor and sponge of miR-7 in the embryonic zebrafish midbrain and islet cells. However, the relationships among ciRS-7, miR-7 and clinical features of HCC remain to be clarified. METHODS: Expression levels of ciRS-7, miR-7 and three miR-7-targeted mRNAs in 108 pairs of HCC and their matched non-tumor tissues were examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The protein production of these three miR-7-targeted mRNAs was further verified by Western blot. The relationship between ciRS-7 level and clinicopathological features as well as the recurrence of HCC patients was analyzed. The univariate and multivariate logistic regression analyses were used to detect the risk factors of hepatic microvascular invasion (MVI). The correlation among ciRS-7, miR-7 and miR-7-targeted mRNAs was evaluated using Spearman's correlation test. RESULTS: There was no significant difference of ciRS-7 expression levels between the HCC tissues and the matched non-tumor tissues (0.67 ± 1.49 vs. 0.44 ± 0.45, p = 0.13), and the ciRS-7 levels in more than half of HCC tissues (65 out of 108, 60.2 %) were down-regulated when compared with their matched non-tumor tissues. However, the expression of ciRS-7 was significantly correlated with the following three clinicopathological characteristics of HCC patients: age <40 years (p = 0.02), serum AFP ≥400 ng/µl (p < 0.01) and hepatic MVI (p = 0.03). Meanwhile, up-regulated ciRS-7 expression was not only an independent risk factor of hepatic MVI but also had a capable predictive ability for MVI (AUC = 0.68, p = 0.001) at the cut-off value of 0.135. Furthermore, the expression of ciRS-7 in HCC tissues with concurrent MVI was inversely correlated with that of miR-7 (r = -0.39, p = 0.007) and positively related with that of two miR-7-targeted genes [PIK3CD (r = 0.55, p < 0.001) and p70S6K (r = 0.34, p = 0.021)]. In addition, the median recurrent time of patients from higher ciRS-7 level group was shorter than that of lower ciRS-7 group (18 vs. 25 months), but no significant difference was observed (p = 0.38). CONCLUSIONS: The expression levels of ciRS-7 were comparable between HCC and matched non-tumor tissues. However, the highly ciRS-7 expression in HCC tissues was significantly correlated with hepatic MVI, AFP level and younger age and thus partly related with the deterioration of HCC. Especially, ciRS-7 was one of the independent factors of hepatic MVI. These data suggested that ciRS-7 may be a promising biomarker of hepatic MVI and a novel therapy target for restraining MVI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yu, L., Gong, X., Sun, L., Zhou, Q., Lu, B., & Zhu, L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158347 · Cited by 356
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Circular RNAs are a large class of animal RNAs with regulatory potency
Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, S. D., Gregersen, L. H., Munschauer, M., et al. (2013) · Nature · doi:10.1038/nature11928 · Cited by 7,990
Natural RNA circles function as efficient microRNA sponges
Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. K., & Kjems, J. (2013) · Nature · doi:10.1038/nature11993 · Cited by 7,985
Identification of Novel Genes Coding for Small Expressed RNAs
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001) · Science · doi:10.1126/science.1064921 · Cited by 4,956
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Salzman, J., Gawad, C., Wang, P. L., Lacayo, N., & Brown, P. O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030733 · Cited by 2,239
Imamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589
RNA integrity and the effect on the real-time qRT-PCR performance
Fleige, S., & Pfaffl, M. W. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.12.003 · Cited by 1,487
Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells
HSU, M.-T., & COCA-PRADOS, M. (1979) · Nature · doi:10.1038/280339a0 · Cited by 1,021
Cited by
CircRNA: functions and properties of a novel potential biomarker for cancer
Meng, S., Zhou, H., Feng, Z., Xu, Z., Tang, Y., Li, P., & Wu, M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0663-2 · Cited by 1,521
Circular RNAs in cancer: opportunities and challenges in the field
Kristensen, L. S., Hansen, T. B., Venø, M. T., & Kjems, J. (2018) · Oncogene · doi:10.1038/onc.2017.361 · Cited by 1,326
Circular RNAs function as ceRNAs to regulate and control human cancer progression
Zhong, Y., Du, Y., Yang, X., Mo, Y., Fan, C., Xiong, F., Ren, D., Ye, X., Li, C., Wang, Y., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0827-8 · Cited by 1,007
Circular RNA and its mechanisms in disease: From the bench to the clinic
Han, B., Chao, J., & Yao, H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.010 · Cited by 788
Circular RNAs: Promising Biomarkers for Human Diseases
Zhang, Z., Yang, T., & Xiao, J. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.07.036 · Cited by 775
CircRNA: a novel type of biomarker for cancer
Zhang, H.-D., Jiang, L.-H., Sun, D.-W., Hou, J.-C., & Ji, Z.-L. (2018) · Breast Cancer · doi:10.1007/s12282-017-0793-9 · Cited by 760
The interplay between m6A RNA methylation and noncoding RNA in cancer
Ma, S., Chen, C., Ji, X., Liu, J., Zhou, Q., Wang, G., Yuan, W., Kan, Q., & Sun, Z. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0805-7 · Cited by 632
Zheng, X., Chen, L., Zhou, Y., Wang, Q., Zheng, Z., Xu, B., Wu, C., Zhou, Q., Hu, W., Wu, C., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1010-6 · Cited by 629
Self-citationAn emerging function of circRNA-miRNAs-mRNA axis in human diseases
Rong, D., Sun, H., Li, Z., Liu, S., Dong, C., Fu, K., Tang, W., & Cao, H. (2017) · Oncotarget · doi:10.18632/oncotarget.19154 · Cited by 516
CircRNAs and cancer: Biomarkers and master regulators
Arnaiz, E., Sole, C., Manterola, L., Iparraguirre, L., Otaegui, D., & Lawrie, C. H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.12.002 · Cited by 415
Bach, D.-H., Lee, S. K., & Sood, A. K. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.02.005 · Cited by 405
Review on circular RNAs and new insights into their roles in cancer
Tang, X., Ren, H., Guo, M., Qian, J., Yang, Y., & Gu, C. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.018 · Cited by 358
Zhou, B., & Yu, J.-W. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.044 · Cited by 356
Circular RNA: a novel biomarker and therapeutic target for human cancers
Lei, B., Tian, Z., Fan, W., & Ni, B. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.28047 · Cited by 313
Circular RNAs (circRNAs) in cancer
Zhou, R., Wu, Y., Wang, W., Su, W., Liu, Y., Wang, Y., Fan, C., Li, X., Li, G., Li, Y., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.03.035 · Cited by 292
Li, Q., Pan, X., Zhu, D., Deng, Z., Jiang, R., & Wang, X. (2019) · Hepatology · doi:10.1002/hep.30671 · Cited by 287
Xiong, D.-D., Dang, Y.-W., Lin, P., Wen, D.-Y., He, R.-Q., Luo, D.-Z., Feng, Z.-B., & Chen, G. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1593-5 · Cited by 280
Pan, H., Li, T., Jiang, Y., Pan, C., Ding, Y., Huang, Z., Yu, H., & Kong, D. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26201 · Cited by 277
Circular RNAs (circRNAs) in Health and Disease
Haque, S., & Harries, L. (2017) · Genes · doi:10.3390/genes8120353 · Cited by 269
Function and clinical significance of circRNAs in solid tumors
Geng, Y., Jiang, J., & Wu, C. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0643-z · Cited by 263
Li, X., Zheng, Y., Zheng, Y., Huang, Y., Zhang, Y., Jia, L., & Li, W. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0976-0 · Cited by 256
Circular RNAs: biogenesis, function, and a role as possible cancer biomarkers
Bolha, L., Ravnik-Glavač, M., & Glavač, D. (2017) · International Journal of Genomics · doi:10.1155/2017/6218353 · Cited by 166
Metadata
- Authors
- Xu, L., Zhang, M., Zheng, X., Yi, P., Lan, C., & Xu, M.
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2016-09-10
- Volume
- 143
- Issue
- 1
- Pages
- 17-27
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- OpenAlex
- W2514180887
- Cited by
- 301
- References
- 38
- FWCI
- 25.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.